Cell therapy momentum is building.
So is the need for sharper insight.
Cell therapy development is no longer defined by CAR T growth alone. Developers are navigating rising complexity across engineering strategies, delivery systems, disease areas, manufacturing models, and regulatory expectations. This report helps you see where the field is moving next, from the rapid rise of in vivo CAR assets to increasing interest in NK cells, macrophages, armoring strategies and solid tumor indications. With 570 drugs and 536 trials added to Beacon Cell Therapy in H1 2026, the report turns a fast-moving and increasingly fragmented landscape into clear, decision-ready insight.
Download your free copy today to get ahead of the curve.
Report Contents
The Drug Landscape
Explore the platforms, cell types, targets and disease areas driving the next phase of cell therapy development, including rapid growth from in vivo CAR, CAR NK cells, macrophages and solid tumor-focused assets.
The Trial Landscape
Track where clinical activity is accelerating, with 536 trials registered to start or already started in 2026, reflecting renewed momentum across cell therapy development.
The Commercial Market
Understand how dealmaking is shifting from broad fundraising toward strategic partnerships, licensing agreements and high-value transactions focused on differentiated platforms and late-stage assets.
The Future of Cell Therapy
Look ahead to the technologies and assets that could define the next phase of the market, including in vivo CAR delivery systems, armoring strategies, emerging assets to watch, and the continued diversification beyond conventional CAR T approaches.
Regulatory Announcements
Review the regulatory milestones shaping the sector, from Investigational New Drug (IND) and Clinical Trial Application (CTA) approvals to first-time drug approvals, Regenerative Medicine Advanced Therapy (RMAT) designations, and regulatory interactions tied to clinical advancement.
Previous Cell Therapy Landscape Reviews
Cell Therapy 2025 Landscape Review
An analysis of the 2025 cell therapy landscape
Cell Therapy H1 2025 Landscape Review
An analysis of the H1 2025 cell therapy landscape
Recent Cell Therapy Resources
Learn More About Cell Therapy
- The Most Comprehensive Way to Search the Cell Therapy Development Landscape: Unique search ontologies based on Cell Therapy drug and trial characteristics
- Market Leading Approach to Cell Therapy Preclinical & Clinical Data Curation: Manual curation of key Cell Therapy research and development data points by Cell Therapy research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Cell Therapy company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
